Braveheart is a clinical-stage biopharmaceutical company developing BHB-1893, an oral small-molecule cardiac myosin inhibitor for hypertrophic cardiomyopathy (HCM). The company currently has no approved products and generates no revenue. BHB-1893 targets both obstructive HCM, where heart muscle thickening blocks blood flow, and non-obstructive HCM, a condition with no currently approved therapies. Braveheart in-licensed BHB-1893 from Hengrui and holds exclusive rights to the candidate outside of Greater China. The company’s business model involves developing and commercializing BHB-1893 as a branded prescription drug, with revenue driven by patient volume and net pricing. Braveheart currently relies on Hengrui for its clinical data and drug supply, though it is developing alternative manufacturing capabilities. Clinical data from trials conducted in China indicate that BHB-1893 may achieve higher response rates with lower impact on heart pump function than existing treatments. Braveheart plans to start global Phase 3 trials, LIONHEART-HCM and NOBLEHEART-HCM, in late 2026 and early 2027. If the drug receives regulatory approval, Braveheart may use its own sales force, contract organizations, or partnerships to reach patients and cardiologists. The company’s operations are focused entirely on this single product candidate and require substantial capital to fund late-stage clinical development.